Cargando…
HIV-1 integrase : mechanism and inhibitor design /
This book comprehensively covers the mechanisms of action and inhibitor design for HIV-1 integrase. It serves as a resource for scientists facing challenging drug design issues and researchers in antiviral drug discovery. Despite numerous review articles and isolated book chapters dealing with HIV-1...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Hoboken, N.J. :
Wiley,
©2011.
|
| Colección: | Wiley series in drug discovery and development.
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000Ma 4500 | ||
|---|---|---|---|
| 001 | EBOOKCENTRAL_ocn757827332 | ||
| 003 | OCoLC | ||
| 005 | 20240329122006.0 | ||
| 006 | m o d | ||
| 007 | cr |n||||||||| | ||
| 008 | 111017s2011 njuaf ob 001 0 eng d | ||
| 010 | |z 2010043285 | ||
| 040 | |a YDXCP |b eng |e pn |c YDXCP |d UIU |d E7B |d N$T |d TEF |d OCLCQ |d NLGGC |d DEBSZ |d MHW |d UKDOC |d OCLCQ |d COO |d OCLCQ |d COCUF |d CHVBK |d MOR |d LIP |d PIFAG |d ZCU |d MERUC |d OCLCQ |d U3W |d OCLCF |d OCLCO |d STF |d WRM |d OCLCO |d ICG |d INT |d VT2 |d OCLCO |d AU@ |d OCLCQ |d WYU |d TKN |d OCLCQ |d DKC |d OCLCO |d OCLCQ |d OCLCA |d CEF |d UX1 |d HS0 |d OCLCA |d VLY |d UKAHL |d OCLCO |d AAA |d OCL |d OCLCQ |d OCLCO |d OCLCL | ||
| 019 | |a 811493902 |a 961689382 |a 962723516 |a 1058109170 |a 1100910559 |a 1162030124 | ||
| 020 | |a 9781118015377 |q (electronic bk.) | ||
| 020 | |a 1118015371 |q (electronic bk.) | ||
| 020 | |a 9781118015353 |q (electronic bk.) | ||
| 020 | |a 1118015355 |q (electronic bk.) | ||
| 020 | |z 9780470184745 |q (cloth) | ||
| 020 | |z 0470184744 |q (cloth) | ||
| 020 | |z 9781118015360 | ||
| 020 | |a 1118015363 | ||
| 020 | |a 9781118015360 | ||
| 024 | 7 | |a 10.1002/9781118015377 |2 doi | |
| 029 | 1 | |a AU@ |b 000053283776 | |
| 029 | 1 | |a CHNEW |b 000938380 | |
| 029 | 1 | |a CHVBK |b 480186871 | |
| 029 | 1 | |a DEBBG |b BV043393613 | |
| 029 | 1 | |a DEBBG |b BV044154531 | |
| 029 | 1 | |a DEBSZ |b 430992017 | |
| 029 | 1 | |a DEBSZ |b 485007665 | |
| 029 | 1 | |a NZ1 |b 14692240 | |
| 029 | 1 | |a AU@ |b 000070758806 | |
| 035 | |a (OCoLC)757827332 |z (OCoLC)811493902 |z (OCoLC)961689382 |z (OCoLC)962723516 |z (OCoLC)1058109170 |z (OCoLC)1100910559 |z (OCoLC)1162030124 | ||
| 050 | 4 | |a QR201.A37 |b H547 2011eb | |
| 060 | 4 | |a 2011 K-532 | |
| 060 | 4 | |a QV 268.5 | |
| 072 | 7 | |a HEA |x 039020 |2 bisacsh | |
| 072 | 7 | |a MED |x 022020 |2 bisacsh | |
| 082 | 0 | 4 | |a 616.97/9201 |2 22 |
| 049 | |a UAMI | ||
| 245 | 0 | 0 | |a HIV-1 integrase : |b mechanism and inhibitor design / |c [edited] by Nouri Neamati. |
| 260 | |a Hoboken, N.J. : |b Wiley, |c ©2011. | ||
| 300 | |a 1 online resource (xiii, 506 pages, 16 unnumbered pages of plates) : |b illustrations (some color) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a data file |2 rda | ||
| 490 | 1 | |a Wiley series on drug discovery and development | |
| 588 | 0 | |a Print version record. | |
| 504 | |a Includes bibliographical references and index. | ||
| 520 | |a This book comprehensively covers the mechanisms of action and inhibitor design for HIV-1 integrase. It serves as a resource for scientists facing challenging drug design issues and researchers in antiviral drug discovery. Despite numerous review articles and isolated book chapters dealing with HIV-1 integrase, there has not been a single source for those working to devise anti-AIDS drugs against this promising target. But this book fills that gap and offers a valuable introduction to the field for the interdisciplinary scientists who will need to work together to design drugs that target HIV-1. | ||
| 505 | 0 | |a HIV-1 INTEGRASE: Mechanism and Inhibitor Design; CONTENTS; PREFACE; CONTRIBUTORS; 1 HIV Life Cycle: Targets for Anti-HIV Agents; 2 pp32 Is Hot; 3 Integrase Mechanism and Function; 4 Structural Studies of Retroviral Integrases; 5 Retroviral Integration Target Site Selection; 6 Pleiotropic Nature of HIV-1 Integrase Mutations; 7 Insights into HIV-1 Integrase-DNA Interactions; 8 Functional Interaction Between Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Integrase; 9 Cellular Cofactors of HIV Integration; 10 Structural Aspects of Lentiviral Integrase-LEDGF Interaction | |
| 505 | 8 | |a 11 Host Factors that Affect Provirus Stability and Silencing12 Assays for Evaluation of HIV-1 Integrase Enzymatic Activity, DNA Binding, and Cofactor Interaction; 13 HIV-1 Integrase Inhibitor Design: Overview and Historical Perspectives; 14 HIV Integrase Inhibitors: From Diketo Acids to Heterocyclic Templates: History of HIV Integrase Medicinal Chemistry at Merck West Point and Merck Rome (IRBM) Leading to Discovery of Raltegravir; 15 Elvitegravir: Novel Quinolone HIV-1 Integrase Strand Transfer Inhibitor; 16 Conformationally Constrained Tricyclic HIV Integrase Inhibitors | |
| 505 | 8 | |a 17 Slow-Onset Kinetics of HIV Integrase Inhibitors and Proposed Molecular Model18 Azaindole Hydroxamic Acids Are HIV-1 Integrase Inhibitors; 19 Simple and Accurate In Vitro Method for Predicting Serum Protein Binding of HIV Integrase Strand Transfer Inhibitors; 20 Role of Metals in HIV-1 Integrase Inhibitor Design; 21 Discovery and Development of Natural Product Inhibitors of HIV-1 Integrase; 22 Development of Styrylquinoline Integrase Inhibitors; 23 Dicaffeoyltartaric Acid and Dicaffeoylquinic Acid HIV Integrase Inhibitors; 24 Design and Discovery of Peptide-Based HIV-1 Integrase Inhibitors | |
| 505 | 8 | |a 25 Nucleotide-Based Inhibitors of HIV Integrase26 Computer-Aided Techniques in Design of HIV-1 Integrase Inhibitors; 27 Application of Protein Covalent Modification to Studying Structure and Function of HIV-1 Integrase and Its Inhibitors; 28 HIV-1 Integrase-DNA Models; 29 New Paradigm for Integrase Inhibition: Blocking Enzyme Function Without Directly Targeting the Active Site; 30 Resistance to Inhibitors of HIV-1 Integrase; INDEX; Colour Plates; Wiley Series in Drug Discovery and Development | |
| 546 | |a English. | ||
| 590 | |a ProQuest Ebook Central |b Ebook Central Academic Complete | ||
| 650 | 0 | |a HIV (Viruses) |x Enzymes. | |
| 650 | 0 | |a HIV (Viruses) |x Enzymes |x Inhibitors. | |
| 650 | 0 | |a Antiviral agents. | |
| 650 | 0 | |a Drugs |x Design. | |
| 650 | 1 | 2 | |a HIV Integrase Inhibitors |x pharmacology |
| 650 | 2 | 2 | |a Drug Design |
| 650 | 2 | 2 | |a HIV Integrase |
| 650 | 2 | |a Antiviral Agents | |
| 650 | 6 | |a Virus de l'immunodéficience humaine |x Enzymes. | |
| 650 | 6 | |a Virus de l'immunodéficience humaine |x Enzymes |x Inhibiteurs. | |
| 650 | 6 | |a Antiviraux. | |
| 650 | 6 | |a Médicaments |x Conception. | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x AIDS & HIV. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x AIDS & HIV. |2 bisacsh | |
| 650 | 7 | |a Drugs |x Design |2 fast | |
| 650 | 7 | |a Antiviral agents |2 fast | |
| 650 | 7 | |a HIV (Viruses) |x Enzymes |2 fast | |
| 700 | 1 | |a Neamati, Nouri. |4 edt | |
| 758 | |i has work: |a HIV-1 integrase (Text) |1 https://id.oclc.org/worldcat/entity/E39PCFGQTWPrjQBxdYqdTdbDMd |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |t HIV-1 integrase. |d Hoboken, N.J. : Wiley, ©2011 |z 9780470184745 |z 0470184744 |w (DLC) 2010043285 |w (OCoLC)670176130 |
| 830 | 0 | |a Wiley series in drug discovery and development. | |
| 856 | 4 | 0 | |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=697476 |z Texto completo |
| 938 | |a 123Library |b 123L |n 20102 | ||
| 938 | |a ebrary |b EBRY |n ebr10494542 | ||
| 938 | |a EBSCOhost |b EBSC |n 391368 | ||
| 938 | |a YBP Library Services |b YANK |n 3537284 | ||
| 938 | |a YBP Library Services |b YANK |n 3588110 | ||
| 938 | |a YBP Library Services |b YANK |n 7146971 | ||
| 938 | |a Askews and Holts Library Services |b ASKH |n AH16072773 | ||
| 994 | |a 92 |b IZTAP | ||